December 03, 2012

Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting

- Scientific presentations include Sanofi JAK2 inhibitor, Clolar®/Evoltra®, Elitek®, Mozobil® and Thymoglobuline® -

 

Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting
- Scientific presentations include Sanofi JAK2 inhibitor, Clolar®/Evoltra®, Elitek®, Mozobil® and Thymoglobuline® -

Paris, France – December 3, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.